Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Metabolic
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
BMS expects 9-13% decline in EPS after Plavix genericisation
05 March 2010
Bristol-Myers Squibb expects its minimum projected non-GAAP EPS to be at least 9% lower in 2013 than its projected 2010 figure, as the loss of patent exclusivity to its lead product, the blood thinner Plavix (clopidogrel), takes full effect. The ...
Antidiabetic GLP-1s only linked to thyroid cancer in rodents, study suggests
05 March 2010
Thyroid cancer risks of anti-diabetic GLP-1 analogues are probably limited to rats and mice, suggests Novo Nordisk -sponsored research published this week in the journal Endocrinology. Investors, who had been expecting the good news, nevertheless ...
Japanese recommendation moves alogliptin closer to the market
04 March 2010
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda 's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following ...
Snow delays Amylin/Lilly's once-weekly Byetta
26 February 2010
Extreme weather has forced the US FDA to push back by one week the PDUFA date for Amylin / Lilly 's once-weekly formulation of Byetta (exenatide), an injectable GLP-1 analogue for the treatment of type 2 diabetes. The drug's new PDUFA is March 12th. ...
Icahn: "I'll fix broken Genzyme"
25 February 2010
Activist investor Carl Icahn has promised a major shake up at Genzyme if he succeeds in winning the four seats he has targeted on the flagging biotech company's board. Mr Icahn contacted Genzyme's management on February 22nd, naming himself and ...
 
2010 Scrip 100 - Metabolic/endocrinology trials analysis
09 December 2009
disease analysis In the metabolic/endocrinology therapeutic area, 233 industry-sponsored Phase II to Phase III trials were initiated between September 1st, 2008, and August 31st, 2009. Of these, ...
2010 Scrip 100 - Innovate to accumulate
09 December 2009
Drug delivery specialists continue to push the boundaries of innovative science, with recent highlights including the emergence of a needle-free migraine treatment and advances in RNAi delivery, ...
Market Insight - Obesity: what next after the CB1 antagonists' failure?
04 November 2008
The European regulator's recent decision to suspend sales of Sanofi-Aventis 's Acomplia (rimonabant) came hot on the heels of setbacks with two other late-stage CB1 antagonist agents, and the ...
 
Editorial: Will Acomplia make a comeback?
28 October 2008
Oh what a tangled web of regulation, healthcare policy and ethics the obesity therapy sector has become. The temporary suspension of Sanofi-Aventis 's Acomplia (rimonabant) in the EU because of ...
 
Inhibiting angiotensin type 1 receptors as a target for diabetes
01 October 2008
Background: Angiotensin type 1 (AT1) receptor blockers (ARBs) are used to treat hypertension and related end-organ damage. ARBs have been recognised as regulators of glucose- and lipid metabolism. ...
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
01 July 2008
Background: Sitagliptin is a novel agent for the treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. Objective: To review the efficacy and ...
Pleiotropic effects of thiazolidinediones
01 May 2008
Background: Insulin resistance and hyperglycemia characterize type 2 diabetes mellitus. Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm